As far as we know, this is the first study to investigate in detail the molecular mechanisms underlying the anti-inflammatory effect of SGD on CI/RP injury, that is, the IL-13-JAK2/STAT6 pathway eliciting M2 microglia promotion. Here, IL13 is linked to specific granule deficiency.